Detalhe da pesquisa
1.
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Br J Clin Pharmacol
; 89(5): 1640-1655, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484341
2.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
3.
The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis.
Br J Clin Pharmacol
; 86(12): 2507-2518, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32415720
4.
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
Ann Rheum Dis
; 76(5): 831-839, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28087506
5.
Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.
Hepatology
; 64(1): 189-99, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26597786
6.
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes.
Am J Hematol
; 96(4): E111-E114, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33448430
7.
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
Eur Respir J
; 46(6): 1740-50, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26493793
8.
Unexpected Toxicology Findings in Rats Dosed With an Antihuman IL-13 Monoclonal Antibody.
Int J Toxicol
; 34(5): 393-407, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26124191
9.
Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
Br J Clin Pharmacol
; 75(5): 1289-98, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23043368
10.
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review.
Clin Pharmacol Ther
; 113(5): 1011-1029, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516352
11.
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.
J Clin Pharmacol
; 62(5): 656-669, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34708423
12.
Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A.
MAbs
; 12(1): 1770018, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32544369
13.
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Adv Ther
; 37(4): 1464-1478, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32078124
14.
Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects.
J Clin Pharmacol
; 59(7): 968-978, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30776134
15.
Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3ß Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.
Cancers (Basel)
; 11(11)2019 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31653008
16.
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.
Leuk Lymphoma
; 64(2): 468-472, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36593729
17.
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Blood Cancer J
; 13(1): 33, 2023 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882409
18.
Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Basic Clin Pharmacol Toxicol
; 121(1): 13-21, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28132416
19.
Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-ß1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants.
Clin Pharmacokinet
; 55(2): 225-36, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26242382
20.
Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
Basic Clin Pharmacol Toxicol
; 117(4): 219-25, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25683750